Yan, S. B., Um, S. L., Peek, V. L., Stephens, J. R., Zeng, W., Konicek, B. W., . . . Walgren, R. A. (2017). MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping. Invest New Drugs.
शिकागो स्टाइल उद्धरणYan, S. Betty, et al. "MET-targeting Antibody (emibetuzumab) and Kinase Inhibitor (merestinib) As Single Agent or in Combination in a Cancer Model Bearing MET Exon 14 Skipping." Invest New Drugs 2017.
एमएलए उद्धरणYan, S. Betty, et al. "MET-targeting Antibody (emibetuzumab) and Kinase Inhibitor (merestinib) As Single Agent or in Combination in a Cancer Model Bearing MET Exon 14 Skipping." Invest New Drugs 2017.
चेतावनी: ये उद्धरण हमेशा 100% सटीक नहीं हो सकते हैं.